Roger Dansey, Seagen CEO (via Merck)

As Mer­ck buy­out buzz heats up, Seagen touts a pos­i­tive up­date on their Pad­cev/Keytru­da com­bo

Most of the news at Seagen these days re­volves around hot buzz about a po­ten­tial $40 bil­lion-plus Mer­ck buy­out. But to­day the fo­cus has shift­ed to an ex­per­i­men­tal com­bo that us­es the phar­ma gi­ant’s big PD-1 can­cer drug Keytru­da.

Ex­ecs at Seagen and their part­ner Astel­las post­ed pos­i­tive top-line num­bers for a com­bi­na­tion of Pad­cev and Keytru­da, not­ing a con­firmed over­all re­sponse rate of 64.5% for front­line urothe­lial can­cer pa­tients who are in­el­i­gi­ble for cis­platin.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.